Novo Nordisk's shares surged by approximately £9 billion after promising trial results for its new anti-obesity pill, which demonstrated significant weight loss comparable to its existing Wegovy injection. This development is crucial as the company competes with Eli Lilly to bring an effective tablet treatment to market, potentially reshaping the obesity treatment landscape and offering new hope for those struggling with weight management.

A recent study has shown that Novo Nordisk's Wegovy pill is just as effective as its injection counterpart, leading to a significant rise in the company's shares. This is great news for those seeking weight management solutions, as it offers a more convenient option without compromising on effectiveness. The findings could potentially expand the market for Wegovy, making it more accessible to individuals who prefer oral medication over injections.